LSX and Jefferies – Insights from the busiest week in European biotech 

The LSX Inv€$tival Showcase kicked off a hectic week in life sciences on 15 November, with these two key events in the biotech calendar making one of the busiest weeks of the year.  Investors and biotechs saw this as a vital chance to meet up and discuss strategies and potential deals amid these dicey market […]

Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022

For those that were unable to attend on Optimum’s 14th Annual Healthcare Investor Conference, or indeed would like a recap of what was shared on the day, we have been releasing the top takeaways from the panels!   Our first panel of the day, chaired by Stephen Hansen, from BioCentury, saw a panel of blue chip […]

Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage

Dan Mahony and Gareth Powell are long time, successful life sciences and healthcare investors. They are luminaries of the UK and European healthcare ecosystem, who have been investing since the late 1990s and initially worked together at Polar Capital where together they set up the biotech and healthcare investment funds. Gareth is still Head of […]

Sector Moves: November 2022

November moves 2022 Analysts and Banking  Kegan McColgan-Bannon has left Singer Capital Markets   Media  Drew Armstrong has been appointed Executive Editor at Endpoints  Andrew Joseph has been appointed International Correspondent at STAT and will be located in London  Elaine Chen has been appointed Cardiovascular Reporter at STAT  Stefania Spezzati has been appointed Chief Correspondent of […]

Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight

Financing growth: Walking the tightrope InsightIn the context of the particularly difficult public markets we have seen recently, Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times, chaired a panel of experts exploring what sources of capital are currently available to fund innovation and the development of new drugs, and what is needed to access […]